Monaco Asset Management Sam Cue Biopharma, Inc. Transaction History

Monaco Asset Management Sam

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$1.24 - $2.18 $101,130 - $177,794	-81,557 Reduced 24.36%	253,185 $313,000
Q1 2024 May 09, 2024	SELL	$1.77 - $3.09 $13,275 - $23,175	-7,500 Reduced 2.19%	334,742 $632,000
Q4 2023 Feb 07, 2024	SELL	$1.72 - $3.1 $30,094 - $54,240	-17,497 Reduced 4.86%	342,242 $903,000
Q3 2023 Nov 07, 2023	SELL	$2.23 - $4.69 $23,789 - $50,032	-10,668 Reduced 2.88%	359,739 $827,000
Q2 2023 Aug 08, 2023	SELL	$3.11 - $4.91 $298,367 - $471,055	-95,938 Reduced 20.57%	370,407 $1.35 Million
Q1 2023 May 11, 2023	SELL	$2.41 - $3.74 $74,305 - $115,311	-30,832 Reduced 6.2%	466,345 $1.66 Million
Q4 2022 Jan 31, 2023	BUY	$2.39 - $3.95 $91,599 - $151,387	38,326 Added 8.35%	497,177 $1.42 Million
Q3 2022 Oct 31, 2022	BUY	$2.23 - $3.37 $33,450 - $50,550	15,000 Added 3.38%	458,851 $1.02 Million
Q2 2022 Aug 01, 2022	BUY	$2.49 - $5.92 $993,138 - $2.36 Million	398,851 Added 886.34%	443,851 $1.11 Million
Q1 2022 May 09, 2022	BUY	$4.41 - $12.28 $198,450 - $552,600	45,000 New	45,000 $220,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Monaco Asset Management Sam, based on Form 13F filings with the SEC.

Stay updated on Monaco Asset Management Sam with notifications on news.